An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revance Therapeutics, Inc. (NASDAQ: RVNC) will release its first quarter 2024 financial results on May 9, 2024, followed by a conference call and webcast to discuss the results and provide a corporate update. The conference call will be accessible for U.S. callers and other locations, with a webcast replay available for 90 days.
Positive
None.
Negative
None.
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.revance.com.
A webcast replay will be available beginning May 9, 2024, at 4.30 p.m. PT / 7.30 p.m. ET to August 9, 2024, at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.
Revance’s global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.
“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.
When will Revance Therapeutics release its first quarter 2024 financial results?
Revance Therapeutics will release its first quarter 2024 financial results on May 9, 2024.
What is the conference call schedule for Revance Therapeutics?
The conference call is scheduled for May 9, 2024, at 4:30 p.m. ET.
How can individuals access the conference call and webcast?
Individuals can dial (833) 470-1428 for U.S. callers and (929) 526-1599 for other locations, or access the webcast link on the investor relations section of Revance's website at www.revance.com.
Is there a webcast replay available for the conference call?
Yes, a webcast replay will be available from May 9, 2024, to August 9, 2024, on the events page of Revance's website.
How long will the webcast replay be accessible?
The webcast replay will be available for 90 days following the completion of the call.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
